Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: any advantage in clarithromycin-resistant strains?
- PMID: 25171023
- DOI: 10.1097/MEG.0000000000000190
Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: any advantage in clarithromycin-resistant strains?
Abstract
Objective: There has been a marked decrease in the eradication rates of Helicobacter pylori infection with standard triple therapy worldwide. Hence, sequential therapy has gained attention as a promising treatment during the last few years. This study was carried out to compare the efficacy of sequential versus standard triple therapy in the context of clarithromycin (CLA) resistance.
Materials and methods: In this study, children between 3 and 18 years of age, who had documented H. pylori infection, were randomized to receive either standard triple or sequential therapy. H. pylori eradication was ascertained using the C-urea breath test 4-6 weeks after the completion of the treatment. Real-time PCR was performed on gastric biopsy samples for assessment of CLA resistance.
Results: In all, 148 children (median age: 12.18±3.51 years) were recruited randomly into the study. The intention-to-treat eradication rates were 50% (37/74) for the sequential treatment group and 52.7% (39/74) for the standard triple treatment group (P=0.87). A total of 136 children completed the study. The per-protocol eradication rates were 56% (37/66) and 55.7% (39/70) for sequential and standard triple therapy groups, respectively. CLA resistance was assessed and 113 children were included in the final analysis. Of 113 participants, 53 were in the sequential treatment group and 60 were in the standard triple treatment group. The success rates of the respective therapies (29/53=54.7% in sequential, 33/60=55% in standard therapy) were similar (P=0.98). CLA resistance was detected in 29 (25.7%) of the patients. Eradication rates with sequential therapy in CLA susceptible and resistant cases were 60.5% (23/38) and 40% (6/15), respectively (P=0.23). The corresponding figures for the standard triple treatment group were 63% (29/46) and 28.6% (4/14) (P=0.033). Although a higher eradication rate was observed in CLA-resistant cases with sequential therapy, the difference did not reach statistical significance (P=0.69).
Conclusion: In this study, standard triple treatment failed to eradicate H. pylori infection in the majority of the children, and sequential therapy offered only a small advantage over standard triple therapy in the eradication of CLA-resistant strains.
Similar articles
-
Sequential therapy versus tailored triple therapies for Helicobacter pylori infection in children.J Pediatr Gastroenterol Nutr. 2011 Dec;53(6):646-50. doi: 10.1097/MPG.0b013e318229c769. J Pediatr Gastroenterol Nutr. 2011. PMID: 21701406 Clinical Trial.
-
Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.Helicobacter. 2012 Aug;17(4):269-76. doi: 10.1111/j.1523-5378.2012.00947.x. Epub 2012 Mar 30. Helicobacter. 2012. PMID: 22759326 Clinical Trial.
-
Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial.J Gastroenterol Hepatol. 2012 Nov;27(11):1675-80. doi: 10.1111/j.1440-1746.2012.07249.x. J Gastroenterol Hepatol. 2012. PMID: 22849546 Clinical Trial.
-
A randomized trial of standard-dose versus half-dose rabeprazole, clarithromycin, and amoxicillin in the treatment of Helicobacter pylori infection.Eur J Gastroenterol Hepatol. 2011 Oct;23(10):865-70. doi: 10.1097/MEG.0b013e3283496502. Eur J Gastroenterol Hepatol. 2011. PMID: 21811161 Review.
-
Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.Dig Dis Sci. 2017 Nov;62(11):3069-3076. doi: 10.1007/s10620-017-4664-1. Epub 2017 Jun 29. Dig Dis Sci. 2017. PMID: 28664410 Review.
Cited by
-
Comparison of multiple treatment regimens in children with Helicobacter pylori infection: A network meta-analysis.Front Cell Infect Microbiol. 2023 Feb 23;13:1068809. doi: 10.3389/fcimb.2023.1068809. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 36909732 Free PMC article.
-
Probiotics improve the efficacy of standard triple therapy in the eradication of Helicobacter pylori: a meta-analysis.Infect Drug Resist. 2016 Dec 7;9:275-289. doi: 10.2147/IDR.S117886. eCollection 2016. Infect Drug Resist. 2016. PMID: 27994474 Free PMC article.
-
The effects of probiotics on the treatment of Helicobacter pylori eradication in children.Saudi Med J. 2015 May;36(5):640. doi: 10.15537/smj.2015.5.12025. Saudi Med J. 2015. PMID: 25935190 Free PMC article. No abstract available.
-
Antibiotic treatment for Helicobacter pylori: Is the end coming?World J Gastrointest Pharmacol Ther. 2015 Nov 6;6(4):183-98. doi: 10.4292/wjgpt.v6.i4.183. World J Gastrointest Pharmacol Ther. 2015. PMID: 26558152 Free PMC article. Review.
-
A randomised controlled clinical study of standard triple therapy, bismuth-based quadruple therapy and sequential therapy for Helicobacter pylori infection in children.BMC Pediatr. 2024 Aug 23;24(1):543. doi: 10.1186/s12887-024-05020-6. BMC Pediatr. 2024. PMID: 39180014 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical